Results 31 to 40 of about 6,938 (195)

TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis [PDF]

open access: yesCell Death & Disease, 2014
AbstractThe relevance of the adaptor protein TNF receptor-associated factor 2 (TRAF2) for signal transduction of the death receptor tumour necrosis factor receptor1 (TNFR1) is well-established. The role of TRAF2 for signalling by CD95 and the TNF-related apoptosis inducing ligand (TRAIL) DRs, however, is only poorly understood.
Karl, I.   +7 more
openaire   +3 more sources

CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways

open access: yesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023
Although the interaction of CD95L (also known as FasL) with its so-called death receptor CD95 (Fas) induces an apoptotic signal responsible for the elimination of infected and cancer cells and maintenance of tissue homeostasis, this receptor can also implement non apoptotic signaling pathways.
Haymour, Layla   +3 more
openaire   +5 more sources

Fermented mistletoe extract as a multimodal antitumoral agent in gliomas [PDF]

open access: yes, 2012
In Europe, commercially available extracts from the white-berry mistletoe (Viscum album L.) are widely used as a complementary cancer therapy. Mistletoe lectins have been identified as main active components and exhibit cytotoxic effects as well as ...
Harter, Patrick Nikolaus   +4 more
core   +2 more sources

FasL Expression in Articular Discs of Human Temporomandibular Joint and Association with Osteoarthrosis [PDF]

open access: yes, 2013
Background Apoptosis is a programme of cell death which does not induce an inflammatory response. Recent previous research has suggested a correlation between temporomandibular internal derangement and apoptosis.
Alanis, Luciana Reis Azevedo   +9 more
core   +2 more sources

The influence of CD95L expression on tumor rejection in mice [PDF]

open access: yesEuropean Journal of Immunology, 2003
AbstractMany tumors express the death ligand CD95L (CD178, APO‐1L, FasL) and can kill activated T cells in vitro. This may enable the tumor cells to suppress anti‐tumor immune responses, a phenomenon called "tumor counterattack". Preliminary evidence of tumor counterattack in human tumors exists. However, CD95L‐expressing tumors are rapidly rejected in
Frederik H, Igney   +2 more
openaire   +2 more sources

APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo [PDF]

open access: yes, 2011
Death receptor targeting has emerged as one of the promising novel approaches of cancer therapy. The activation of one such prototypic death receptor, CD95 (Fas/APO-1), has remained controversial because CD95 agonistic molecules have exhibited either too
Aulwurm, S   +7 more
core   +1 more source

CD95/Fas ligand mRNA is toxic to cells

open access: yeseLife, 2018
CD95/Fas ligand binds to the death receptor CD95 to induce apoptosis in sensitive cells. We previously reported that CD95L mRNA is enriched in sequences that, when converted to si/shRNAs, kill all cancer cells by targeting critical survival genes ...
Will Putzbach   +8 more
doaj   +1 more source

Differences in CD95L Levels and Blood Test Results in Primary and Secondary Dengue Infection Patients

open access: yesMajalah Kedokteran Bandung, 2022
Dengue is a disease caused by dengue virus (DENV) that is transmitted mainly by the female Aedes aegypti mosquito. There are four serotypes of DEN, leading to a possibility that a person may be infected four times by this virus, albeit with different ...
Nurfadly Nurfadly   +2 more
doaj   +1 more source

Myeloid-derived suppressor cell, arginase-1, IL-17 and cl-CD95L: an explosive cocktail in lupus? [PDF]

open access: yes, 2016
International audienceComment on: Wu H, Zhen Y, Ma Z, et al. Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus.
Flynn, Robin J, Legembre, Patrick
core   +3 more sources

CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells [PDF]

open access: yes, 2016
Glioblastoma (GBM) is one of the most aggressive types of cancer with limited therapeutic options and unfavorable prognosis. Stemness and non-classical epithelial-to-mesenchymal transition (ncEMT) features underlie the switch from normal to neoplastic ...
Chen, S.   +13 more
core   +2 more sources

Home - About - Disclaimer - Privacy